Overcoming the Achilles' heel of photodynamic therapy
Photodynamic therapy (PDT) has been applied to treat a wide range of medical conditions, including wet age-related macular degeneration psoriasis, atherosclerosis, viral infection and malignant cancers. However, the tissue penetration limitation of excitation light hinders the widespread clinical us...
Saved in:
| Published in | Chemical Society reviews Vol. 45; no. 23; pp. 6488 - 6519 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
21.11.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Photodynamic therapy (PDT) has been applied to treat a wide range of medical conditions, including wet age-related macular degeneration psoriasis, atherosclerosis, viral infection and malignant cancers. However, the tissue penetration limitation of excitation light hinders the widespread clinical use of PDT. To overcome this "Achilles' heel", deep PDT, a novel type of phototherapy, has been developed for the efficient treatment of deep-seated diseases. Based on the different excitation sources, including near-infrared (NIR) light, X-ray radiation, and internal self-luminescence, a series of deep PDT techniques have been explored to demonstrate the advantages of deep cancer therapy over conventional PDT excited by ultraviolet-visible (UV-Vis) light. In particular, the featured applications of deep PDT, such as organelle-targeted deep PDT, hypoxic deep PDT and deep PDT-involved multimodal synergistic therapy are discussed. Finally, the future development and potential challenges of deep PDT are also elucidated for clinical translation. It is highly expected that deep PDT will be developed as a versatile, depth/oxygen-independent and minimally invasive strategy for treating a variety of malignant tumours at deep locations.
This review summarizes the latest progress in deep photodynamic therapy (PDT), which overcomes the Achilles' heel of PDT. |
|---|---|
| Bibliography: | Wenpei Fan received his PhD in 2015 from Shanghai Institute of Ceramics, Chinese Academy of Sciences (SICCAS), under the direction of Prof. Wenbo Bu and Prof. Jianlin Shi. He then worked with Prof. Peng Huang and Prof. Xiaoyuan (Shawn) Chen at Shenzhen University and National Institutes of Health (NIH) as a postdoctoral fellow in 2015. His research interest focuses on the design, synthesis, and biomedical applications of multifunctional nanotheranostics. Peng Huang received his PhD in Biomedical Engineering from the Shanghai Jiao Tong University in 2012. He then joined the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institutes of Health (NIH) as a postdoctoral fellow under the supervision of Prof. Xiaoyuan (Shawn) Chen. In 2015, he moved to Shenzhen University as a Distinguished Professor. His research focuses on the design, synthesis, and biomedical applications of molecular imaging contrast agents, stimuli-responsive programmed targeting drug delivery systems, and activatable theranostics. Xiaoyuan (Shawn) Chen received his PhD in Chemistry from the University of Idaho in 1999. He joined the University of Southern California as an Assistant Professor of Radiology in 2002. He then moved to Stanford University in 2004. In 2009, he joined NIBIB as a Senior Investigator and Lab Chief. Dr Chen has published over 500 papers and numerous books and book chapters. He is the founding editor of the journal Theranostics. His lab is interested in using molecular imaging as a tool for better understanding biology, early diagnosis of disease, monitoring therapy response, and guiding drug discovery/development. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 ObjectType-Article-1 ObjectType-Feature-2 |
| ISSN: | 0306-0012 1460-4744 1460-4744 |
| DOI: | 10.1039/c6cs00616g |